NATuRe CHemisTRy revealed that a second C-H activation event is required to form the bis-cyclometallated Ru(ii) complex III, prior to the oxidative addition step that leads to the Ru(iv) species IV (Fig. 1c) . The detection and characterization of the bis-cycloruthenated intermediate III was made possible by kinetic studies, which allowed us to hypothesize its fundamental role in the catalytic cycle. Furthermore, our
T he installation of the biphenyl fragment via cross-coupling reactions has become a staple of drug design 1, 2 . Due to the pivotal role of aromatic non-covalent interactions in proteinligand recognition 3 , the placement of aryl motifs in drug candidates can lead to derivatives with higher activities [4] [5] [6] [7] . Although during the past years some statistical studies have tried to start to rationalize the impact of aromatic ring count on drug developability [8] [9] [10] , it is widely acknowledged that only a small portion of the available chemical space has been explored and that safe compounds can be identified outside the conventional drug-like chemical space 8, 11, 12 . Consequently, the development of reliable C-H arylation technologies would provide a more sustainable alternative to cross-coupling reactions 13 and grant access to a rapid and valuable exploration of the structural diversity via late-stage C-H arylation [14] [15] [16] [17] , which would make them extremely desirable within drug discovery and development.
The vast majority of drugs contain several polar functionalities, often as part of oxygen, nitrogen and sulfur heterocycles [18] [19] [20] , that are essential to maximize the drug-target interaction and maintain acceptable levels of pharmacokinetics and toxicity 21 . However, despite the need to manipulate polar functionalities in medicinal chemistry, a statistical analysis revealed that "the more polar products in an array tended to systematically fail more often in synthesis", which may correlate with the crisis of productivity of the drug-discovery process 22 . Specifically, polar groups are often problematic in C-H activation as the presence of Lewis basic heteroatoms can promote catalyst poisoning or substrate decomposition [23] [24] [25] . Moreover, in directed C-H activation reactions, strongly coordinating moieties add a further challenge as they can outcompete the directing group (DG) for catalyst binding, and thus prevent its approach into the proximity of the targeted C-H bond 26 . Nonetheless, despite the historical bias towards para-substitution observed in medicinal chemistry, which favours the synthesis of 'flat' products 27 , orthodirected C-H activation protocols have the capability of expanding the chemical space. Due to the twisting and disruption of the planar structure, ortho regioisomers have different physicochemical properties relative to para and meta ones, and they may prove themselves valuable when exploring new target classes that necessitate different spatial arrangements to bind and attain the desired effect 2 .
In the context of ortho-directed C-H arylation reactions with aryl (pseudo)halides, whereas palladium-catalysed processes are by far the most studied 13, [28] [29] [30] [31] [32] [33] , the use of ruthenium often brings several benefits. In addition to being more than 15 times cheaper than palladium, electrophiles such as aryl chlorides, triflates and bromides can be coupled by ruthenium with similar levels of efficiency 13, 34 . Since the pioneering work on the Ru(ii)-catalysed C-H arylation of DG-containing arenes with aryl halides in 2001 35 , tremendous efforts have been dedicated towards the establishment of more general and efficient reaction conditions 13, 34, [36] [37] [38] [39] [40] . However, state-ofthe-art methodologies still require high temperatures and often a several-fold excess of the aryl (pseudo)halide (Fig. 1a) . Furthermore, the exceptional binding affinity of the Ru(ii) metal centre to sp 2 nitrogen atoms-widespread in ortho DGs-has not flourished as an in-built selection device able to discriminate between sp 2 nitrogens over other heteroatoms or functional groups that possess lesser coordinating abilities. Thus, directed Ru(ii)-catalysed C-H activation reactions have yet to be shown to withstand polar sensitive groups, which are ubiquitous in pharmaceuticals and natural products. This is probably because the harsh working conditions commonly required in these methodologies facilitate detrimental reaction paths, either by preventing the desired DGcatalyst interaction or by initiating thermal decomposition of these delicate functionalities.
Here we report the discovery of a key catalytic species in the mechanism of the Ru(ii)-catalysed C-H arylation of DG-containing arenes with aryl (pseudo)halides. For nearly two decades, this reaction has been proposed to operate via a catalytic cycle (Fig. 1b) that involves an initial C-H activation step to form cycloruthenated species I, which undergoes oxidative addition with the aryl halide to generate the Ru(iv) intermediate II. The latter, after the reductive elimination step, will then release the biaryl product, which restarts the cycle 13, 34, 41, 42 . We speculate that this oversimplified mechanism has, to date, prevented the discovery of truly reactive catalysts. Contrary to previous postulations, our mechanistic investigations NATuRe CHemisTRy studies reveal that cycloruthenated complexes like I (Fig. 1d , RuB) are able to catalyse the C-H arylation at remarkably low temperatures, with equimolar amounts of the aryl (pseudo)halide. Owing to the commercial and competitive aspects of drug discovery, robust and established methodologies are relentlessly preferred. Consequently, the uptake of new synthetic methods in medicinal chemistry is a function of the extents of the substrate scope presented in the methodology 43, 44 . Therefore, with the aim to provide a NATuRe CHemisTRy truthful and solid platform to evaluate the possibility of implementing our technology in the synthesis of drug-like compounds, we targeted heavily functionalized molecules by performing late-stage arylation on pharmaceuticals, agrochemicals, natural products and organic electronic materials.
results and discussion
Kinetic evidence that supports the involvement of a bis-cycloruthenated intermediate. Recently, we described the first Ru(ii)-catalysed C-H arylation methodology for 'simple' electron-deficient arenes 45 . During the development of this methodology, we discovered that, contrary to previous hypotheses 41 , the p-cymene ligand present in state-of-the-art ruthenium catalysts (Fig. 1a, RuA) is an inhibitor in the reaction. This disparity prompted a more thorough investigation of the general mechanism of Ru(ii)-catalysed C-H arylation. We began our investigation by examining the mechanism of the directed arylation of 2-(o-tolyl)pyridine 1 with 5-iodo-m-xylene 2 to form 4 (Fig. 2) . We assessed the reactivity of two proposed catalytic intermediates, Ru1 and Ru2 (corresponding to complex I in Fig. 1b,c) , in their stoichiometric reaction with aryl iodide 2 in the presence of KOAc in NMP (N-methyl-2-pyrrolidone) at 90 °C (Fig. 2) . Surprisingly, both Ru1 and Ru2 reacted sluggishly with 2 , which suggests that a more complex mechanism than that depicted in Fig. 1b was in operation. Specifically, the reaction profile of Ru1 revealed: (1) a fast release of p-cymene 3 , (2) a rapid build-up of decomplexed 2-(o-tolyl)pyridine 1 , which then decreased over time, and (3) an induction period in the formation of biaryl 4 that correlated with the evolution of free 1 (Fig. 2, graph i) . p-Cymenefree Ru2 displayed a similar behaviour, albeit with a much faster arylation rate (Fig. 2, graph ii) , which confirms the inhibitory role of the p-cymene ligand in this directed arylation. Importantly, the observed formation and consumption of free 1 is consistent with kinetics in which this species is a reaction intermediate in the arylation process. Thus, we hypothesized that a C-H activation step between an η 6 -arene-free cycloruthenated species, such as Ru2 and 1 , must happen before reaction with iodoarene 2 (for example, I to III in Fig. 1c) . Indeed, when the concentration profiles for the arylation reactions of Ru1 and Ru2 were monitored after the addition of 0.2 equiv. of 2-(o-tolyl)pyridine 1 , a fast consumption of 1 and a significant increase in the arylation rate were observed (Fig. 2 , graphs iii and iv). Furthermore, in agreement with the generation of a bis-cyclometallated complex like III (Fig. 1c) , the omission of the base required for C-H activation, KOAc, substantially reduced the arylation rate 46 (Supplementary Section 3).
Detection and reactivity of the bis-cycloruthenated intermediate. To validate further this mechanistic hypothesis, we followed the reaction of cyclometallated complex Ru3 with 2-arylpyridine 5 (Fig. 3, light F NMR spectroscopy. A rapid ligand exchange took place at room temperature between the acetonitrile ligands of Ru3 and NMP to produce Ru4 (Fig. 3 , spectra iiii). After 180 minutes at 80 °C, Ru3 /Ru4 had quantitatively reacted with 5 to form the predicted bis-cyclometallated Ru(ii) species Ru5 , whose structure was confirmed by X-ray analysis. Then, iodoarene 2 was added and the reaction was monitored at 25 °C (Fig. 3, light  yellow shading) . Over 600 minutes, Ru5 quantitatively reacted with 2 to form the arylated product 6 , along with the cyclometallated complexes Ru6 and Ru4 derived from reductive elimination. This experiment is fully consistent with our mechanistic hypothesis, and provides strong evidence that the catalytic cycle reported in Fig. 1c is, indeed, operating.
Monocycloruthenated complexes as a superior class of catalysts.
Having discovered evidence for the intermediacy of a bis-cycloru- NATuRe CHemisTRy thenated complex, we compared the rate of the reaction catalysed by Ru2 and KOAc to the rates with Ru7 and Ru8 , which are the most widely employed state-of-the-art ruthenium catalysts 13, 34, 46, 47 (Fig. 4a) .
Thus, the C-H arylation of 2-phenylpyridine 7 with 5-iodo-m-xylene 2 was monitored over time at 35 °C. Remarkably, although the cyclometallated Ru2 catalyst afforded a combined yield of 89% of mono (1 equiv.)
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From sulfaphenazole and strychnine Reaction set up under identical optimized conditions for each particular case, but Ru7 and Ru8 were used instead of Ru9 without KOAc or KOBz; the yield was evaluated by NMR spectroscopy. OLED, organic light-emitting diode.
Articles
NATuRe CHemisTRy (8 ) and diarylated (9 ) adducts in 420 minutes, Ru7 and Ru8 were essentially inactive. These results demonstrate that catalysts based on on-cycle intermediates, such as I (RuB in Fig. 1d) , possess a far superior catalytic activity than the commonly employed Ru(ii) species (RuA in Fig. 1a) , which enables reactivity to occur at unprecedentedly low temperatures. However, 8% of biaryl 4 , derived from arylation of the cyclometallating ligand in Ru2 , was also formed. A similar scenario was also observed with other aryl (pseudo)halides (Supplementary Section 6). It was hypothesized that this was due to the non-selective reductive elimination from a Ru(iv) complex that featured two different cyclometallated arenes, which implies that catalysts such as Ru2 still suffered from a major drawback. In an attempt to overcome this limitation, we tested cycloruthenated complexes that featured different nitrogen ligands. Gratifyingly, the N,Ndimethylbenzylamine-containing Ru9 provided diarylated adduct 9 in 96% yield and suppressed the undesired 'catalyst arylation' degradation pathway that produces 10 and 11 (Fig. 4b) .
Investigation of the scope of the reaction with respect to the aryl (pseudo)halide coupling partners. Having identified Ru9 as an ideal catalyst able to couple equimolar amounts of DG-containing arenes with aryl (pseudo)halides under exceptionally mild reaction conditions, we decided to demonstrate the synthetic utility of this catalytic system. Towards this aim, pharmaceuticals and natural products that possess an aromatic chloride, bromide, iodide or a phenol moiety transformed into its triflate derivative (X1-X34 ), were selected as coupling partners for the C-H arylation of 2-(o-tolyl)pyridine 1 (Fig. 5) . The scope of the reaction is striking; many ubiquitous heterocycles and functional groups in medicinal chemistry [18] [19] [20] were well tolerated and provided good-to-excellent yields (A1 -A34 ). O-, N-, S-and C-containing (hetero)cycles, such as piperidine (A10 and A18 ), pyridine (A17 , A18 and A32 ), piperazine (A8 , A9 , A13 , A14 and A16 ), azepane (A7 ), indole (A3 and A31 ), carbazole (A32 ), phenothiazine (A14 ), dihydrodibenzoazepine (A12 ), dibenzodiazepine (A13 ), thioxanthene (A15 ), triazolone (A8 and A9 ), pyrimidinedione (A23 ), pyridone (A23 ), morphinan (A30 ), steroid (A26 and A27 ), β -lactam (A33 ), glucose (A34 ), coumarin (A28 ), chromane (A24 ), phtalazinone (A7 ), benzothiadiazine (A6 ) and thiazinane (A4 ), were shown to be compatible with our system. More specifically, sensitive functional groups, which included tertiary (A12 , A15 , A17 , A20 , A21 and A31 ) and secondary amines (A11 ), carbamates (A5 and A18 ), a sulfonylurea (A19 ), alkenes (A15 , A18 , A20 , A25 and A26 ), acryloyl groups (A26 and A28 ), benzylic (A10 , A33 ), tertiary (A10 and A30 ), secondary (A27 and A34 ) and primary alcohols (A34 ), an acetal (A34 ), a thiohemiaminal derivative (A4 ), amidine derivatives (A6 and A13 ), cyclopropyl groups (A23 , A26 and A30 ), an aniline (A21 ), a carboxylic acid (A1 ), an aldehyde (A29 ), amides (A1 , A19 , A23 and A25 ), esters (A2 , A3 and A26 ), an α -amino ketone (A11 ) and ketones (A2 and A30 ) were all tolerated. The efficiency of this catalytic system was also demonstrated by conducting the reaction with clomipramine X12 on a 10 g scale with the catalyst loading lowered to 3 mol%. The corresponding product, A12 , was yielded in 95% after a simple aqueous work-up. To highlight further the robustness of our method, bromantane could be used in its pharmaceutical formulation of Ladasten, X22, to provide A22 in 94% yield despite the presence of possibly interfering excipients.
Investigation of the scope of the reaction with respect to the DG-containing arene coupling partners. We then turned our attention to the generality of this reaction with respect to the DG-containing coupling partner (Fig. 6a) . Towards this purpose, we tested the 2-phenylpyridine derivative atazanavir N1, a peptidomimetic human immunodeficiency virus-1 protease inhibitor that features a complex azadipeptide isoester, which provided B1 in 80% yield. This methodology is not limited to 2-arylpyridine analogues:
other heterocycles with a sp 2 -nitrogen DG, which include imidazopyridines (zolimidine to give B2 and zolpidem to give B3 ), dihydrodibenzoazepin-2-ones (diazepam to B4 and flurazepam to B5 ), purine (to B6), oxazole (oxaprozin to B7), pyrazole (sulfaphenazole to B8 ) and 1,2,4-triazole (TAZ (3-(biphenyl-4-yl)-5-(4-t-butylphenyl)-4-phenyl-4H-1,2,4-triazole) to B9) gave good-to-excellent yields of the corresponding ortho-arylated functional molecules (B2 -B9). Consequently, more sensitive moieties, such as sulfonyl (B2 ), the hemiaminal ether of the purine riboside B6, sulfonamide (B8 ) and chloride (B4 and B5 ) were also tolerated. Remarkably, the diazepam derivative C1 was obtained in 95% yield in a one-pot fashion simply by the sequential addition of iodoarene 2 and 2-(o-tolyl)pyridine 1 . To illustrate further the power of our catalytic system, the coupling between two highly functionalized drugs was achieved (Fig. 6b) . Atazanavir N1, zolpidem N3, flurazepam N5 and sulfaphenazole N8 were, respectively, reacted with trametinib X23, clozapine X13, hymecromone derivative X28 and Br-strychnine X20 and provided superb yields of the targeted compounds (D1 -D4 ). Conversely, when the current state-of-the-art Ru(ii) catalysts Ru7 and Ru8 were tested, neither catalyst afforded D1 -D4 in synthetically useful yields (Fig. 6b, bottom right) .
Conclusion
Our study highlights the factors that promote oxidative addition at Ru(ii) centres in C-H arylation processes of N-chelating substrates with aryl (pseudo)halides and demonstrates how comprehensive mechanistic studies can inform the development of more-efficient catalysts. In particular, we identified a bis-cycloruthenated species as the key intermediate that is required for the oxidative addition step to occur. Based on this knowledge, we designed a more-robust catalytic system capable of performing late-stage arylation on complex functionalized molecules and that tolerates functional groups generally considered incompatible with C-H arylation.
According to the PubChem database, there are 6.4 million (hetero)aromatic compounds with a sp 2 nitrogen suitable for orthoruthenation via a five-membered intermediate, and 22 million (hetero)aromatic chlorides, bromides, iodides and phenols that have biological activity. Owing to this impressive pool of potential coupling partners that bear diverse functionalities, our efficient and cost-effective technology promises to be a powerful and reliable tool for drug discovery and development. Finally, we anticipate that the presented mechanistic discovery could be extended to other C-H activation transformations under current development.
Methods
General procedure for C-H arylation. All of the liquid reagents and solvents were dried over 4 Å molecular sieves and degassed with three freeze-pump-thaw cycles prior to use. KOAc and K 2 CO 3 were dried at 140 °C in a vacuum oven for 48 h prior to use. Unless otherwise indicated, in a glovebox, an oven-dried crimpcap microwave vial equipped with a magnetic stirring bar was charged with Ru9 (10 mol%), KOAc (30 mol%), K 2 CO 3 (2-4 equiv.), the appropriate DG-containing arene (1 equiv.) and aryl (pseudo)halide (1 equiv.) and NMP (1 M). The vial was capped and stirred at 35 °C for 24 h. Upon completion, the vial was transferred out of the glovebox and the crude mixture was loaded onto a silica gel column and purified by flash chromatography.
Data availability. The data reported in this paper are available in the Supplementary Information. Metrical parameters for the structure of biscyclometallated complex Ru5 are available free of charge from the Cambridge Crystallographic Data Centre (https://www.ccdc.cam.ac.uk/data_request/cif) under reference number CCDC 1567316.
